- Home
- GEG vs BYSI Comparison
GEG vs BYSI Comparison
Compare GEG & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- BYSI
- Stock Information
- Founded
- GEG 1994
- BYSI 2010
- Country
- GEG United States
- BYSI United States
- Employees
- GEG N/A
- BYSI N/A
- Industry
- GEG Computer Software: Prepackaged Software
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- GEG Technology
- BYSI Health Care
- Exchange
- GEG Nasdaq
- BYSI Nasdaq
- Market Cap
- GEG 60.4M
- BYSI 71.0M
- IPO Year
- GEG N/A
- BYSI 2017
- Fundamental
- Price
- GEG $2.07
- BYSI $2.23
- Analyst Decision
- GEG
- BYSI
- Analyst Count
- GEG 0
- BYSI 0
- Target Price
- GEG N/A
- BYSI N/A
- AVG Volume (30 Days)
- GEG 9.8K
- BYSI 152.4K
- Earning Date
- GEG 08-28-2025
- BYSI 08-11-2025
- Dividend Yield
- GEG N/A
- BYSI N/A
- EPS Growth
- GEG N/A
- BYSI N/A
- EPS
- GEG N/A
- BYSI N/A
- Revenue
- GEG $19,626,000.00
- BYSI N/A
- Revenue This Year
- GEG N/A
- BYSI N/A
- Revenue Next Year
- GEG N/A
- BYSI N/A
- P/E Ratio
- GEG N/A
- BYSI N/A
- Revenue Growth
- GEG 64.34
- BYSI N/A
- 52 Week Low
- GEG $1.70
- BYSI $0.98
- 52 Week High
- GEG $2.33
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- GEG 44.46
- BYSI 46.60
- Support Level
- GEG $1.96
- BYSI $2.33
- Resistance Level
- GEG $2.15
- BYSI $2.50
- Average True Range (ATR)
- GEG 0.09
- BYSI 0.32
- MACD
- GEG -0.02
- BYSI -0.10
- Stochastic Oscillator
- GEG 29.73
- BYSI 1.59
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.